A new study reveals how the price of treatments for a devastating disease quadrupled over the past decade
- In a study published by JAMA Neurology, researchers found that multiple sclerosis patients who have Medicare Part D-government-funded health insurance that covers prescription drug costs-have seen their medication prices quadruple from 2006 to 2016.
- The rise in drug prices has also translated to an increase in patients' out-of-pocket expenses, which increased by seven times over that decade, from $372 a year to $2,673 a year.
- Alvaro San-Juan-Rodriguez, an author of the study, told Business Insider that the expenses are "exorbitant" and mean limited drug access for multiple sclerosis patients.
- Visit Business Insider's homepage for more stories.
View all Offers
OnePlus Nord 2 5G (Gray Sierra, 8GB RAM, 128GB Storage)₹ 29999Buy On
- 19% OFF
Redmi Note 10 (Aqua Green, 4GB RAM, 64GB Storage) -Amoled Dot Display | 48MP Sony Sensor IMX582 | Snapdragon 678 Processor₹ 12999₹ 15999Buy On
- 18% OFF
Redmi 9 (Carbon Black, 4GB RAM, 64GB Storage) | 2.3GHz Mediatek Helio G35 Octa core Processor₹ 8999₹ 10999Buy On
OnePlus Nord 2 5G (Blue Haze, 8GB RAM, 128GB Storage)Buy On
- 18% OFF
Redmi 9A (Nature Green, 2GB RAM, 32GB Storage) | 2GHz Octa-core Helio G25 Processor | 5000 mAh Battery₹ 6999₹ 8499Buy On
MS is a degenerative inflammatory disease of the central nervous system, which affects almost one million people in the US, according to the National Multiple Sclerosis Society.The study focused on patients using Medicare Part D, government-funded health insurance that helps cover prescription drug costs. Medicare Part D is available to seniors, as well as to some individuals with disabilities.
The cost of prescription drugs has drawn attention from both Republicans and Democrats, with the Trump administration proposing a number of fixes. Still, the administration has taken little action so far and drug prices continue to increase. Often patients end up paying a significant portion of the cost.Study authors including Alvaro San-Juan-Rodriguez and Inmaculada Hernandez set out to study the increasing price of multiple sclerosis drugs to see how they affected patients and the healthcare system. They said increasing costs can make it difficult for patients to afford their medications.
MS drug costs have increased exponentially, causing patients to pay more out-of-pocketThe study showed that as the total cost of MS drugs increased, so did the amount that patients had to pay out-of-pocket. Looking at Medicare data, the study breaks down the price increases separately for drug list prices (the cost before any rebates), patients' out-of-pocket expenses, and Medicare expenses.
The study looked at an average of 2.8 million Medicare beneficiaries every year from 2006 - 2016. The annual cost of treatment with self-administered disease modifying therapies (DMTs) for MS patients increased from $18,660 in 2006 to $75,847 in 2016, averaging a 12.8% increase annually, based on the list price of the treatments.
Medicare's actual spending increased by 10 times over that decade, from $7,794 to $79,411 on average. And average out-of-pocket spending increased by seven times from $372 to $2673 over the 10 years.The chart below from the study shows how the prices of different MS therapies all largely increased at a similar pace.
The chart is courtesy of JAMA Network.
The chart is courtesy of JAMA Network.
Even with new therapies entering the market, drug prices continue to increase
Some of the most popular drugs for MS on the market like Copaxone, Tecfidera and Avonex reduce the frequency of relapses for MS patients."These drugs offer great benefits to patients," Rodriguez said. "It helps with vision loss, pain, fatigue and muscle weakness and much more."
"The uptake for the new therapies since they entered the market a couple years ago is considerable," Hernandez told Business Insider. "It's hard to predict the future, but we hope these trends will not be maintained. There should be more competition so we don't see these drug prices continue."Rodriguez said he hopes this study will be a call to action for drug prices to not continuously inflate.
"We observed how prices of drugs are more than four fold and the key driver is out-of-pocket expenses which reduces patient access for the vital medication they need," Rodriguez said
- Let budget bring resurgence, TN CM Stalin advises officials
- Tokyo Olympics: PV Sindhu bags bronze medal in women's singles badminton for India
- GST revenue collection for July rises by 33% with ₹1,16,393 crore
- Policy ignition: India's satellite navigation sector set for higher growth trajectory
- COVID-19 cases in Kerala are spiking due to good detection, better reporting and early easing of restrictions